Tissue Diagnostic Market By Product Type, Technology, Disease, and
End User - Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018–2026
Tissue diagnosis is important tool in diagnosis, monitoring, and management of different types of
cancer conditions. Recognition of sign and symptoms of disease are done through biopsy, a process
of taking sample from region of interest such as skin, tissue or tumor for further diagnosis. Biopsy
are primarily done to look for cancer detection or to detect rejection of transplanted organ draft.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1112
Biopsy is done to identify likely cause of cancerous and non-cancerous tissue, which are unable to
detect through CT-scan or X-rays. Depending on area of sample collection various biopsy
procedures are done such as endoscopic biopsy, bone marrow biopsy, skin biopsy, kidney biopsy,
liver biopsy, and prostate biopsy. Furthermore biopsy can be done using needle biopsy, CT guided
biopsy, Ultrasound biopsy, and surgical biopsy for the tissue diagnostic. According to the American
journal of Nephrology, 2015, Australia has the highest numbers of annual renal biopsy rates (215
persons/million person/year) followed by the Finland (176 persons/million person/year) and U.S.
(175 persons/million person/year). The increased numbers of biopsy procedure likely to fuel the
growth of tissue diagnostic market, in near future.
Rising prevalence of different cancer incidences is major driving factor boosting the tissue
diagnostic market. According to American cancer Society (ACS), 1.6 million new cases of cancer
diagnosed in the U.S., in 2016. In addition, increase research funding in cancer treatment and
growing healthcare expenditure likely to show gradual rise in tissue diagnostic market. National
Cancer Institute, in 2015, spends US$ 4,480 million on various types of cancer research which
includes breast cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, leukemia,
ovarian cancer and uterine cancer.
Rise in the prevalence of cancer incidences to boost the tissue diagnostic market